CorMedix publishes Q3 2026 earnings and corporate update call transcript
CRMD•CorMedix reported quarterly revenue of $54.5 million, down from $104.3 million a year earlier, and narrowed 2026 adjusted EBITDA guidance to $130 million–$140 million. It deferred 2027 DefenCath revenue guidance and expects the Heron asset acquisition to close in the first quarter of 2027.
1. Quarterly results and guidance
CorMedix held its third-quarter 2026 earnings call with CEO Joseph Todisco, CFO Susan Blum and Chief Operating and Commercial Officer Liz Hurlburt. Quarterly revenue fell to $54.5 million from $104.3 million a year earlier, primarily reflecting lower DefenCath pricing following its reimbursement transition. The company narrowed full-year 2026 adjusted EBITDA guidance to $130 million–$140 million and maintained revenue guidance of $325 million–$345 million.
2. 2027 outlook
Management deferred 2027 DefenCath revenue guidance until early 2027, pending clarity on customer pricing, utilization and Medicare Advantage contracts. The Heron asset acquisition is expected to close in the first quarter of 2027 and contribute $125 million–$150 million in revenue that year.




